Drug intelligence / Profile preview

emibetuzumab + erlotinib

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

Emibetuzumab + erlotinib is a combination therapy consisting of emibetuzumab, a humanized IgG4 monoclonal bivalent MET antibody that blocks both ligand-dependent and ligand-independent hepatocyte growth factor (HGF)/MET signaling, and erlotinib, an EGFR tyrosine kinase inhibitor. This combination was developed to target both EGFR and MET pathways in non-small cell lung cancer (NSCLC), particularly in EGFR-mutant tumors where MET signaling is a known resistance mechanism to EGFR inhibition.

Brand names: Tarceva
Other names: emibetuzumabLY2875358LY-2875358LY 2875358erlotinib

Targets

EGFR (Epidermal growth factor receptor)MET (Mesenchymal-epithelial transition factor receptor)

Beyond the preview

Go deeper on emibetuzumab + erlotinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on emibetuzumab + erlotinib.

Explore the full profile